Lobetyolin ameliorates DSS-induced ulcerative colitis in mice by alleviating inflammation, restoring barrier function, and modulating gut microbiota–metabolite interactions
Observational analysis shows lobetyolin reduces inflammation and improves barrier function in mice with colitis, suggesting it can benefit UC treatment.
Key Points
Lobetyolin significantly reduces inflammation and improves gut microbiota in DSS-induced colitis mice, enhancing barrier function.
Key metrics include decreased IL-6 and IL-1β, indicative of inflammation control and improved gut health.
The approach involves immunohistochemistry and analysis of short-chain fatty acids to assess gut function and microbial balance.
These findings suggest lobetyolin's potential as a multi-target treatment for ulcerative colitis, highlighting its role in gut health.